Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells

Cancer Research

Volumn 63, Issue 7, 2003, Pages 1676-1683

  Kudo, Daisuke ^a   Rayman, Patricia ^a   Horton, Claudine ^a   Cathcart, Martha K ^a   Bukowski, Ronald M ^a   Thornton, Mark ^a   Tannenbaum, Charles ^a   Finke, James H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; GANGLIOSIDE; GLYCOSPHINGOLIPID; PROTEIN BCL 2; PROTEIN BCL XL;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; KIDNEY CARCINOMA; MEDIATOR RELEASE; MICROENVIRONMENT; NICK END LABELING; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

APOPTOSIS; BCL-X PROTEIN; CARCINOMA, RENAL CELL; CASPASES; CELL COMMUNICATION; COCULTURE TECHNIQUES; CYTOCHROME C GROUP; ENZYME ACTIVATION; GANGLIOSIDES; HUMANS; JURKAT CELLS; KIDNEY NEOPLASMS; MITOCHONDRIA; PROPANOLAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLIDINES; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0037379733     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Wang, R. F., Zeng, G., Johnston, S. F., Voo, K., and Ying, H. T cell-mediated immune responses in melanoma: implications for immunotherapy. Crit. Rev. Oncol. Hematol., 43: 1-11, 2002.
2. Boon, T., Coulie, P. G., and Van den Eynde, B. Tumor antigens recognized by T cells. Immunol. Today, 18: 267-268, 1997.
3. Uzzo, R. G., Kolenko, V., Froelich, C. J., Tannenbaum, C., Molto, L., Novick, A. C., Bander, N. H., Bukowski, R., and Finke, J. H. The T cell death knell: immunemediated tumor death in renal cell carcinoma. Clin. Cancer Res., 7: 3276-3281, 2001.
4. Nielsen, M. B., and Marincola, F. M. Melanoma vaccines: the paradox of T cell activation without clinical response. Cancer Chemother. Pharmacol., 46 (Suppl.): S62-S66, 2001.
5. Finke, J., Ferrone, S., Frey, A., Mufson, A., and Ochoa, A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol. Today, 20: 158-160, 1999.
6. Pettit, S. J., Seymour, K., O'Flaherty, E., and Kirby, J. A. Immune selection in neoplasia: towards a microevolutionary model of cancer development. Br. J. Cancer, 82: 1900-1906, 2000.
7. Seliger, B., Ritz, U., Abele, R., Bock, M., Tampe, R., Suttcr, G., Drexler, I., Huber, C., and Ferrone, S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res., 61: 8647-8650, 2001.
8. Garrido, F., and Algarra, I. MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res., 83: 117-158, 2001.
9. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., Lennon, V. A., Celis, E., and Chen, L. Tumorassociated B7-HI promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med., 8: 793-800, 2002.
10. Liu, B., Peng, D., Lu, Y., Jin, W., and Fan, Z. A novel single amino Acid deletion caspase-8 mutant in cancer cells that lost proapoptotic activity. J. Biol. Chem., 277: 30159-30164, 2002.
11. Uzzo, R. G., Rayman, P., Kolenko, V., Clark, P. E., Bloom, T., Ward, A. M., Molto, L., Tannenbaum, C., Worford, L. J., Bukowski, R., Tubbs, R., Hsi, E. D., Bander, N. H., Novick, A. C., and Finke, J. H. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res., 5: 1219-1229, 1999.
12. Uzzo, R. G., Rayman, P., Novick, A. C., Bukowski, R. M., and Finke, J. H. Molecular mechanisms of immune dysfunction in renal cell carcinoma. In: R. M. Bukowski and A. C. Novick (eds.), Renal Cell Carcinoma: Molecular Biology, Immunology and Clinical Management, pp. 63-78. Totowa: Humana Press, 2000.
13. Gastman, B. R., Atarshi, Y., Reichert, T. E., Saito, T., Balkir, L., Rabinowich, H., and Whiteside, T. L. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res., 59: 5356-5364, 1999.
14. Gastman, B. R., Yin, X. M., Johnson, D. E., Wieckowski, E., Wang, G. Q., Watkins, S. C., and Rabinowich, H. Tumor-induced apoptosis of T cells: amplification by a mitochondrial cascade. Cancer Res., 60: 6811-6817, 2001.
15. Gastman, B. R., Johnson, D. E., Whiteside, T. L., and Rabinowich, H. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood, 95: 2015-2023, 2000.
16. Whiteside, T. L., and Rabinowich, H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother., 46: 175-184, 1998.
17. Koyama, S., Koike, N., and Adachi, S. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J. Cancer Res. Clin. Oncol., 128: 73-79, 2002.
18. Wischhusen, J., Jung, G., Radovanovic, I., Beier, C., Steinbach, J. P., Rimner, A., Huang, H., Schulz, J. B., Ohgaki, H., Aguzzi, A., Rammensee, H. G., and Weller, M. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res., 62: 2592-2599, 2002.
19. Uzzo, R. G., Rayman, P., Kolenko, V., Clark, P. E., Cathcart, M. K., Bloom, T., Novick, A. C., Bukowski, R. M., Hamilton, T., and Finke, J. H. Renal cell carcinomiderived gangliosides suppress nuclear factor-κB activation in T cells. J. Clin. Investig., 104: 769-776, 1999.
20. Finke, J. H., Rayman, P., George, R., Tannenbaum, C. S., Kolenko, V., Uzzo, R., Novick, A. C., and Bukowski, R. M. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-κB suppression. Clin. Cancer Res., 7: 940s-946s, 2001.
21. Sorice, M., Parolini, I., Sansolini, T., Garofalo, T., Dolo, V., Sargiacomo, M., Tai, T., Peschle, C., Torrisi, M. R., and Pavan, A. Evidence for the existence of gangliosideenriched plasma membrane domains in human peripheral lymphocytes. J. Lipid Res., 38: 969-980, 1997.
22. Ritter, G., and Livingston, P. O. Ganglioside antigens expressed by human cancer cells. Semin. Cancer Biol., 2: 401-409, 1991.
23. Stallcup, W. B. Involvement of gangliosides and glycoprotein fibronectin receptors in cellular adhesion to fibronectin. Exp. Cell Res., 177: 90-102, 1988.
24. Satoh, M., Handa, K., Saito, S., Tokuyama, S., Ito, A., Miyao, N., Orikasa, S., and Hakomori, S. Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential. Cancer Res., 56: 1932-1938, 1996.
25. Kopitz,J., von Reitzenstein,C., Burchert, M., Cantz, M., and Gabius, H. J. Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture. J. Biol. Chem., 273: 11205-11211, 1998.
26. Iwabitchi, K., Yamamura, S., Prinetti, A., Handa, K., and Hakomori, S. GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B 16 cells. J. Biol. Chem., 273: 9130-9138, 1998.
27. Black, P. H. Shedding from the cell surface of normal and cancer cells. Adv. Cancer Res., 32: 75-199, 1980.
28. Ladisch, S., Gillard, B., Wong, C., and Ulsh, L. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res., 43: 3808-3813, 1983.
29. Kloppel, T. M., Keenan, T. W., Freeman, M. J., and Morre, D. J. Glycolipid-bound sialic acid in serum: increased levels in mice and humans bearing mammary carcinomas. Proc. Natl. Acad. Sci. USA, 74: 3011-3013, 1977.
30. Heitger, A., and Ladisch, S. Gangliosides block antigen presentation by human monocytes. Biochim. Biophys. Acta, 1303: 161-168, 1996.
31. Ladisch, S., Becker, H., and Ulsh, L. Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim. Biophys. Acta, 1125: 180-188, 1992.
32. Ladisch, S., Ulsh, L., Gillard, B., and Wong, C. Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. J. Clin. Invest., 74: 2074-2081, 1984.
33. Li, R., Villacreses, N., and Ladisch, S. Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res., 55: 211-214, 1995.
34. Ladisch, S., Kitada, S., and Hays, E. F. Gangliosides shed by tumor cells enhance tumor formation in mice. J. Clin. Investig., 79: 1879-1882, 1987.
35. McKallip, R., Li, R., and Ladisch, S. Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol., 163: 3718-3726, 1999.
36. Valentino, L., Moss, T., Olson, E., Wang, H. J., Elashoff, R., and Ladisch, S. Shed tumor gangliosides and progression of human neuroblastoma. Blood, 75: 1564-1567, 1990.
37. Ito, A., Handa, K., Withers, D. A., Satoh, M., and Hakomori, S. Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. FEBS Lett., 504: 82-86, 2001.
38. Ebert, T., Bander, N. H., Finstad, C. L., Ramsawak, R. D., and Old, L. J. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res., 50: 5531-5536, 1990.
39. Deng, W., Li, R., and Ladisch, S. Influence of cellular ganglioside depletion on tumor formation. J. Natl. Cancer Inst. (Bethesda), 92: 912-917, 2000.
40. Ladisch, S., and Gillard, B. A solvent partition method for microscale ganglioside purification. Anal. Biochem., 146: 220-231, 1985.
41. Kolenko, V., Uzzo, R. G., Bukowski, R., Bander, N. H., Novick, A. C., Hsi, E. D., and Finke, J. H. Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res., 59: 2838-2842, 1999.
42. Kolenko, V., Bloom, T., Rayman, P., Bukowski, R., Hsi, E., and Finke, J. Inhibition of NF-κB activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J. Immunol., 163: 590-598, 1999.
43. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counter-attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
44. Kristal, B. S., and Brown, A. M. Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition. J. Biol. Chem., 274: 23169-23175, 1999.
45. Garcia-Ruiz, C., Colell, A., Paris, R., and Femandez-Checa, J. C. Direct interaction of GD3 ganglioside with mitochondria generates reactive oxygen species followed by mitochondrial permeability transition, cytochrome c release, and caspase activation. FASEB J., 14: 847-858, 2000.
46. Caricchio, R., D'Adamio, L., and Cohen, P. L. Fas, ceramide and serum withdrawal induce apoptosis via a common pathway in a type II Jurkat cell line. Cell Death Differ., 9: 574-580, 2002.
47. Fulda, S., Meyer, E., Friesen, C., Susin, S. A., Kroemer, G., and Debatin, K. M. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene, 20: 1063-1075, 2001.
48. Fulda, S., Meyer, E., and Debatin, K. M. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res., 60: 3947-3956, 2000.
49. Dumont, A., Hehner, S. P., Hofmann, T. G., Ueffing, M., Droge, W., and Schmitz, M, L. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-κB. Oncogene, 18: 747-757, 1999.
50. Murphy, K. M., Streips, U. N., and Lock, R. B. Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2. Oncogene, 18: 5991-5999, 1999.
51. Gross, A., McDonnell, J. M., and Korsmeyer, S. J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev., 13: 1899-1911, 1999.
52. Finke, J. H., Rayman, P., Hart, L., Alexander, J. P., Edinger, M. G., Tubbs, R. R., Klein, E., Tuason, L., and Bukowski, R. M. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-γ secretion, and proliferation. J. Immunother. Emphasis Tumor Immunol., 15: 91-104, 1994.
53. Echchakir, H., Dorothee, G., Vergnon, I., Menez, J., Chouaib, S., and Mami-Chouaib, F. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc. Natl. Acad. Sci. USA, 99: 9358-9363, 2002.
54. Pilch, H., Hohn, H., Neukirch, C., Freitag, K., Knapstein, P. G., Tanner, B., and Maeurer, M. J. Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor. Clin. Diagn. Lab. Immunol., 9: 267-278, 2002.
55. Lu, W., Dong, Z., Donawho, C., and Fidler, 1. J. Specific innnunotherapy against occult cancer metastases. Int. J. Cancer, 100: 480-485, 2002.
56. Shurin, M. R., Kirkwood, J. M., and Esche, C. Cytokine-based therapy for melanoma: pre-clinical studies. Forum (Genova), 10: 204-226, 2000.
57. Ling, W., Rayman, P., Uzzo, R., Clark, P., Kim, H. J., Tubbs, R., Novick, A., Bukowski, R., Hamilton, T., and Finke, J. Impaired activation of NFκB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor. IκBα. Blood., 92: 1334-1341, 1998,
58. Nakagomi, H., Pisa, P., Pisa, E. K., Yamamoto, Y., Halapi, E., Backlin, K., Juhlin, C., and Kiessling, R. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer, 63: 366-371, 1995.
59. Wang, Q., Redovan, C., Tubbs, R., Olencki, T., Klein, E., Kudoh, S., Finke, J., and Bukowski, R. M. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int. J. Cancer, 61: 780-785, 1995.
60. Alexander, J. P., Kudoh, S., Melsop, K. A., Hamilton, T. A., Edinger, M. G., Tubbs, R. R., Sica, D., Tuason, L., Klein, E., and Bukowski, R. M. T cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res., 53: 1380-1387, 1993.
61. Bhunia, A. K., Schwarzmann, G., and Chatterjce, S. GD3 recruits reactive oxygen species to induce cell proliferation and apoptosis in human aortic smooth muscle cells. J. Biol. Chem., 277: 16396-16402, 2002.
62. Desagher, S., Osen-Sand, A., Nichols, A., Eskes, R., Montessuit, S., Lauper, S., Maundrell, K., Antonsson, B., and Martinou, J. C. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol., 144: 891-901, 1999.
63. Esposti, M. D., Hatzinisiriou, I., McLennan, H., and Ralph, S. Bcl-2 and mitochondrial oxygen radicals. New approaches with reactive oxygen species-sensitive probes. J. Biol. Chem., 274: 29831-29837, 1999.
64. Armstrong, J. S., Steinauer, K. K., French, J., Killoran, P. L., Walleczek, J., Kochanski, J., and Knox, S. J. Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization. Exp. Cell Res., 262: 170-179, 2001.
65. Ryan, J. L., and Shinitzky, M. Possible role for glycosphingolipids in the control of immune responses. Eur. J. Immunol., 9: 171-175, 1979.
66. Bergelson, L. D., Dyatlovitskaya, E. V., Klyuchareva, T. E., Kryukova, E. V., Lemenovskaya, A. F., Matveeva, V. A., and Sinitsyna, E. V. The role of glycosphingolipids in natural Immunity. Gangliosides modulate the cytotoxicity of natural killer cells. Eur. J. Immunol., 19: 1979-1983, 1989.
67. Ito, A., Levery, S. B., Saito, S., Satoh, M., and Hakomori, S. A novel ganglioside isolated from renal cell carcinoma. J. Biol. Chem., 276: 16695-16703, 2001.